2-[2-oxo-2-(propan-2-ylamino)ethoxy]-N-propan-2-ylacetamide | 90716-92-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[2-oxo-2-(propan-2-ylamino)ethoxy]-N-propan-2-ylacetamide
• CAS: 90716-92-0
• 化学式: C₁₀H₂₀N₂O₃
• mdl: MFCD00746601
• 分子量: 216.28
• InChiKey: SORJKGWVZLUDGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[2-oxo-2-(propan-2-ylamino)ethoxy]-N-propan-2-ylacetamide 、 氢化铝锂 以41%的产率得到
  参考文献：
  名称：

  KRAKOWIAK, K.;KOTELKO, B., ACTA POL. PHARM., 1983, 40, N 3, 313-318

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2'-氧化二乙酰氯 、 异丙胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以76%的产率得到2-[2-oxo-2-(propan-2-ylamino)ethoxy]-N-propan-2-ylacetamide
  参考文献：
  名称：

  Phase-Separable Aqueous Amide Solutions as a Thermal History Indicator

  摘要：

  合成了几种新的酰胺化合物的水溶液，用作低温运输食品和其他产品的简单热历史指示剂。通过改变溶液中的酰胺-水比例、水中的氯化钠浓度以及酰胺化合物的类型，可以自由调整水溶液的相变温度。预计这些水溶液可以作为新的热历史指示剂应用。

  DOI：

  10.1271/bbb.80625

文献信息

• COMPOUND WITH ANTICANCER ACTIVITY
  申请人：KYOWA KIRIN CO., LTD.

  公开号：US20210024540A1

  公开（公告）日：2021-01-28

  A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L 1 and L 2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).

  提供具有抗癌活性的化合物，或其药用可接受的盐。所使用的化合物表示为以下式（I）或其药用可接受的盐： （其中，L1和L2相同或不同，每个代表从(A)到(F)式组成的一种式子所代表的基团，S代表从(S1)到(S18)式组成的一种式子所代表的基团）。
• Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
  申请人：ARDELYX, INC

  公开号：US10376481B2

  公开（公告）日：2019-08-13

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开内容涉及用于治疗与体液潴留或盐负荷过重相关的疾病的化合物和方法，如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病和过氧化物酶体增殖激活受体（PPAR）γ激动剂诱导的体液潴留。本公开还涉及治疗高血压的化合物和方法。本公开还涉及治疗胃肠道疾病的化合物和方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• IAP bir domain binding compounds
  申请人：Boudreault Alain

  公开号：US20080069812A1

  公开（公告）日：2008-03-20

  Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG, Q and Q 1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.
• IAP BIR domain binding compounds
  申请人：Boudreault Alain

  公开号：US20080207525A1

  公开（公告）日：2008-08-28

  Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG, Q and Q 1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.
• IAP BIR DOMAIN BINDING COMPOUNDS
  申请人：Boudreault Alain

  公开号：US20100221261A1

  公开（公告）日：2010-09-02

  Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG, Q and Q 1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.